Eleanor de Groot Ph.D.
Net Worth
Last updated:
What is Eleanor de Groot Ph.D. net worth?
The estimated net worth of Dr. Eleanor de Groot Ph.D. is at least $2,847,787 as of 22 Dec 2021. He owns shares worth $205,263 as insider, has earned $197,624 from insider trading and has received compensation worth at least $2,444,900 in ZIOPHARM Oncology, Inc..
What is the salary of Eleanor de Groot Ph.D.?
Dr. Eleanor de Groot Ph.D. salary is $488,980 per year as Executive Vice President of Operations in ZIOPHARM Oncology, Inc..
How old is Eleanor de Groot Ph.D.?
Dr. Eleanor de Groot Ph.D. is 56 years old, born in 1969.
What stocks does Eleanor de Groot Ph.D. currently own?
As insider, Dr. Eleanor de Groot Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| ZIOPHARM Oncology, Inc. (ZIOP) | Executive Vice President of Operations | 237,106 | $0.87 | $205,263 |
What does ZIOPHARM Oncology, Inc. do?
ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.
Eleanor de Groot Ph.D. insider trading
ZIOPHARM Oncology, Inc.
Dr. Eleanor de Groot Ph.D. has made 3 insider trades between 2020-2021, according to the Form 4 filled with the SEC. Most recently he sold 20,132 units of ZIOP stock worth $25,568 on 22 Dec 2021.
The largest trade he's ever made was exercising 24,890 units of ZIOP stock on 2 Jan 2020. As of 22 Dec 2021 he still owns at least 237,106 units of ZIOP stock.
ZIOPHARM Oncology key executives
ZIOPHARM Oncology, Inc. executives and other stock owners filed with the SEC:
- Dr. Eleanor de Groot Ph.D. (56) Executive Vice President of Operations
- Dr. Raffaele Baffa M.D., Ph.D. (64) Chief Medical Officer and Executive Vice President of R&D
- Mr. Zuie-Chin Huang M.B.A. (59) Executive Chairman